Results 151 to 160 of about 125,916 (291)

Nucleoside Reverse Transcriptase Inhibitor [PDF]

, 2020
openaire   +1 more source

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

Advanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao, Xiaoli Cui, Huizhu Du, Zhuoqun Wang, Chang Liu, Linxin Zhang, Jianing Qi, Di Yang, Hui Yu, Shuang Yan, Wei Liu, Haiming Sun, Mengyang Wang   +12 more
wiley   +1 more source

Site‐Selective Ligand Selection by Mutational Profiling for Covalent RNA Targeting

Angewandte Chemie, EarlyView.
Using a mutational profiling approach an RNA‐targeted covalent probe was developed that is highly selective for the FMN riboswitch. The covalency was further supported by mass spectrometry experiments. The covalent probe selectively modifies the riboswitch at low micromolar concentrations within 10 min and remains functional when applied to an entire ...
Phillip Yesley, Georgia Poulladofonou, Danny Incarnato, Willem A. Velema   +3 more
wiley   +2 more sources

Reverse transcriptase inhibitors in Aicardi-Goutières syndrome: A crossover clinical trial. [PDF]

Dev Med Child Neurol
Crow YJ, Briggs TA, Eleftheriou D, Parida A, Battison C, Giddings A, Kennel T, Parker RA, AGS‐RTIs Study Group.   +8 more
europepmc   +1 more source

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells. [PDF]

Pharmaceuticals (Basel), 2023
Lipke K, Kubis-Kubiak A, Piwowar A.
europepmc   +1 more source

Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase [PDF]

, 2019
Ping Gao, Xiqiang Cheng, Lin Sun, Shu Song, Mar Álvarez, Joanna Luczkowiak, Christophe Pannecouque, Erik De Clercq, Luis Menéndez‐Arias, Peng Zhan, Xinyong Liu   +10 more
openalex   +1 more source

Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin (EPO) Due to EPO c.‐136 G>A Germline Mutation

American Journal of Hematology, EarlyView.
A novel erythropoietin (EPO) promoter mutation (c.‐136 G>A) causes autosomal dominant erythrocytosis via non‐renal expression of EPO. ABSTRACT We previously reported a five‐generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.‐136 G>A).
Lucie Lanikova, Dusan Hrckulak, Veronika Zimolova, Felipe R. Lorenzo, Jihyun Song, Katerina Vecerkova, Olga Babosova, Linda Berkova, Vladimir Korinek, Steve Elliott, Josef T. Prchal   +10 more
wiley   +1 more source

Design, Synthesis, and Biological Activity of Amine-Type Cyclopentanepyridinone Derivatives as HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors. [PDF]

ACS Omega
Castro-Perea NV, Rodríguez-Vega G, Abarca-Magaña JC, Ruiz-Rivera MB, Medina-Franco JL, Huerta L, Chávez D.   +6 more
europepmc   +1 more source

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. [PDF]

Commun Chem, 2023
Jiang X, Huang B, Rumrill S, Pople D, Zalloum WA, Kang D, Zhao F, Ji X, Gao Z, Hu L, Wang Z, Xie M, De Clercq E, Ruiz FX, Arnold E, Pannecouque C, Liu X, Zhan P.   +17 more
europepmc   +1 more source

Biological evaluation of inhibitors of reverse transcriptase from HIV type-1

, 2015
Hitendra Kumar Lautre, Taïbi Ben Hadda, Snigdha Das, Ajai K. Pillai   +3 more
openalex   +1 more source